Amyloidosis Progress
Diagnosis, treatment and research: how the care of cardiac amyloidosis has evolved over recent decades, based on a review of three parallel advances.
Newsroom
News
-
-
Amyloidosis and physical activity
Amyloidosis can affect the heart, kidneys and nerves. Why regular physical activity adapted to each person can play a useful role alongside treatment.
-
Cardiac amyloidosis is under-diagnosed
Cardiac amyloidosis often goes unrecognised, even by doctors. What it is, a case seen in an emergency department, and why earlier diagnosis matters.
-
The WHF forum in Switzerland
At a World Heart Federation forum in Geneva in May 2023, patient representatives, including for ATTR cardiomyopathy, spoke about rare heart diseases.
-
Clinical trial accessible to everybody
Plain language summaries of key ATTR amyloidosis clinical trial publications are now available in seven languages, to make results accessible to patients.
-
A successful therapeutic trial for Amyloidosis
Early results for an antibody designed to clear transthyretin amyloid deposits were presented at a heart failure congress, pointing to a possible new approach.
-
What is ATTRv amyloidosis?
ATTRv amyloidosis is the hereditary form of ATTR. Its symptoms, its impact on daily life, how it is diagnosed and the treatment options, explained simply.
-
The 4th European ATTR amyloidosis meeting
The 4th European ATTR amyloidosis meeting for patients and physicians takes place on 2 and 3 November 2023, on site and online, with two programmes.
-
What is the status of amyloidosis research?
First described in 1838, amyloidosis remains a young field of research. An overview of what is known about its causes, current treatments and research.